Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1994P - The tumour immune contexture and theranostic markers expression in patients with gastric carcinoma

Date

17 Sep 2020

Session

E-Poster Display

Topics

Pathology/Molecular Biology

Tumour Site

Presenters

Oksana Sulaieva

Citation

Annals of Oncology (2020) 31 (suppl_4): S1052-S1064. 10.1016/annonc/annonc295

Authors

O. Sulaieva1, A. Mashukov2, S. Kirkilevsky3

Author affiliations

  • 1 Department Of Histopathology, Laboratory of Pathology "CSD Health Care", 03022 - Kyiv/UA
  • 2 Department Of Oncology, Odessa National Medical University, 65069 - Odessa/UA
  • 3 Research Department, National Institute of Cancer, 03022 - Kyiv/UA

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1994P

Background

Tumour immune microenvironment (TIME) assessment is thought to be effective tool for evaluation of tumour-host interplay and prognostication of different cancers development, including gastric carcinoma (GC). As inflammatory signaling is closely related with DNA-repair pathways, there could be the link between GC immune contexture and DNA-repair enzymes expression defining response to different therapies. This study aimed to assess the relations between TIME and theranostic markers expression in GC of different histological types.

Methods

In this retrospective study we assessed 50 cases (29 males and 21 females; 52.5±2.18 years old) of the locally advanced or metastatic GC naïve to preoperative chemotherapy and radiotherapy. Among enrolled cases there were 15 diffuse GC and 35 intestinal-type GC according to Lauren’s classification. The number of CD8+, CD68+ and CD163+ cells as well as expression of ERCC1, TOPO2A and PD-L1 were assessed immunohistochemically.

Results

Intestinal-type GCs were associated with enhanced infiltration by CD8+ cells (P=0.002), high rate of PD-L1 expression (P=0.03) and CD163+ cells number. In contrast, diffuse GCs demonstrated mostly immune desert phenotype and CD68+ macrophages were the most prevalent within tumour nests and stroma (P<0.001). The lowest rate of ERCC1 expression was found in GC with high CD8+ infiltration (P =0.047) regardless histological type. Whereas high TOPO2A expression was mostly related with highly CD8-infiltrated GCs of intestinal type (P=0.018). Notably, PD-L1 expression was more often in intestinal type GCs rich in CD163+ macrophages (P=0.03).

Conclusions

Various histological types of GC demonstrated distinct immunogenisity and were related with different expression of theranostic biomarkers that could affect both immune escape mechanisms and resistance to therapies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Laboratory of Pathology \"CSD Health Care\".

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.